Real-World Management and Survival Outcomes in Patients with Primary or Recurrent Retroperitoneal Liposarcoma: A Single-Center Retrospective Cohort Study
- 1Department of Urology, National Hospital Organization Kyushu Cancer Center, Notame 3-1-1, Minami-ku, Fukuoka 811-1395, Japan
Abstract
Background/Objectives: Histological subtype and resection completeness are established prognostic factors in retroperitoneal liposarcoma, but evidence often derives from resected primary disease. We characterized management and post-referral survival in a referral cohort. Methods: We retrospectively analyzed 61 patients managed from May 2015 to September 2025. Overall survival (OS) was measured from first presentation at our center. Kaplan–Meier and exploratory Cox analyses were performed, allowing the association between tumor diameter and mortality to vary over time. Results: Forty-two patients had primary disease, and 19 had recurrent disease; 12 had well-differentiated liposarcoma (WDLPS), and 49 had dedifferentiated liposarcoma (DDLPS). Among 24 patients who underwent surgery, 21 had macroscopically complete (R0/R1) resection. Twenty-five patients died. No deaths occurred in WDLPS; median OS was 29.8 months in DDLPS (p = 0.008). In DDLPS, recurrent versus primary disease was not associated with OS (hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.41–2.38). Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 (n = 6 in the entire cohort) was associated with poorer OS (adjusted HR, 8.03; 95% CI, 2.20–29.36), and the association between tumor diameter and mortality varied over time (adjusted interaction HR, 1.44; 95% CI, 1.07–1.95). Conclusions: Observed post-referral survival differed by histological subtype. Among patients with DDLPS, no survival difference between primary and recurrent disease was demonstrated, but the wide CI and referral-related survivor selection preclude an inference of equivalence. Associations involving performance status and time-varying tumor diameter were exploratory and require external validation.
Related
- Case Report: Recurrent retroperitoneal dedifferentiated liposarcoma after surgery
- Anaesthesia management of a giant retroperitoneal liposarcoma: a case report and literature review.
- Clinical Management and Risk Stratification of Retroperitoneal Sarcoma with a Focus on Locally Recurrent Disease.
- Giant primary retroperitoneal myxofibrosarcoma mimicking myxoid liposarcoma: a diagnostic and surgical challenge
- En bloc multivisceral resection for a giant retroperitoneal dedifferentiated liposarcoma: technical considerations.
BibTeX
@article{kijima2026realworld,
title = {{Real-World Management and Survival Outcomes in Patients with Primary or Recurrent Retroperitoneal Liposarcoma: A Single-Center Retrospective Cohort Study}},
author = {Atsuhiro Kijima and Nobuki Furubayashi and Takahito Negishi and Motonobu Nakamura},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203334},
url = {https://www.mdpi.com/2072-6694/18/20/3334},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-World Management and Survival Outcomes in Patients with Primary or Recurrent Retroperitoneal Liposarcoma: A Single-Center Retrospective Cohort Study
AU - Atsuhiro Kijima
AU - Nobuki Furubayashi
AU - Takahito Negishi
AU - Motonobu Nakamura
PY - 2026
DA - 2026/10/15
JO - Cancers
DO - 10.3390/cancers18203334
UR - https://www.mdpi.com/2072-6694/18/20/3334
AB - Background/Objectives: Histological subtype and resection completeness are established prognostic factors in retroperitoneal liposarcoma, but evidence often derives from resected primary disease. We characterized management and post-referral survival in a referral cohort. Methods: We retrospectively analyzed 61 patients managed from May 2015 to September 2025. Overall survival (OS) was measured from first presentation at our center. Kaplan–Meier and exploratory Cox analyses were performed, allowing the association between tumor diameter and mortality to vary over time. Results: Forty-two patients had primary disease, and 19 had recurrent disease; 12 had well-differentiated liposarcoma (WDLPS), and 49 had dedifferentiated liposarcoma (DDLPS). Among 24 patients who underwent surgery, 21 had macroscopically complete (R0/R1) resection. Twenty-five patients died. No deaths occurred in WDLPS; median OS was 29.8 months in DDLPS (p = 0.008). In DDLPS, recurrent versus primary disease was not associated with OS (hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.41–2.38). Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 (n = 6 in the entire cohort) was associated with poorer OS (adjusted HR, 8.03; 95% CI, 2.20–29.36), and the association between tumor diameter and mortality varied over time (adjusted interaction HR, 1.44; 95% CI, 1.07–1.95). Conclusions: Observed post-referral survival differed by histological subtype. Among patients with DDLPS, no survival difference between primary and recurrent disease was demonstrated, but the wide CI and referral-related survivor selection preclude an inference of equivalence. Associations involving performance status and time-varying tumor diameter were exploratory and require external validation.
SN - 2072-6694
ER -